Compare NPK & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NPK | JANX |
|---|---|---|
| Founded | 1905 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 1994 | 2021 |
| Metric | NPK | JANX |
|---|---|---|
| Price | $148.31 | $16.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 18 |
| Target Price | N/A | ★ $36.24 |
| AVG Volume (30 Days) | 73.0K | ★ 746.1K |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | ★ 0.67% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.99 | N/A |
| Revenue | ★ $503,524,000.00 | $10,000,000.00 |
| Revenue This Year | N/A | $194.24 |
| Revenue Next Year | $10.60 | N/A |
| P/E Ratio | $149.86 | ★ N/A |
| Revenue Growth | ★ 29.70 | N/A |
| 52 Week Low | $91.28 | $12.12 |
| 52 Week High | $158.17 | $35.34 |
| Indicator | NPK | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 50.40 | 45.68 |
| Support Level | $143.12 | $15.83 |
| Resistance Level | $156.44 | $19.16 |
| Average True Range (ATR) | 4.15 | 0.91 |
| MACD | -0.12 | -0.05 |
| Stochastic Oscillator | 43.79 | 16.32 |
National Presto Industries Inc has an electric product portfolio consisting of household appliances, ammunition, and diapers. The company operates in three segments, namely Defense, Housewares/Small Appliance, and Safety. The defense segment, which is engaged in manufacturing 40mm ammunition, precision mechanical and electro-mechanical assemblies, and medium caliber cartridge cases, performs Load, Assemble, and Pack (LAP) operations on ordnance-related products for the U.S. Government and prime contractor. While the Housewares/Small Appliance segment designs, markets, and distributes housewares and small electrical appliances, the safety segment provides safety technology empowering organizations and individuals to protect what is more important.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.